Breathe Easier With Tadalafil Therapy for Dyspnea in COPD-PH

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 126 participants.

Also called NCT05937854

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 126 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05937854
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT05937854. Randomized; quadruple masking; primary purpose treatment. Start 2024-04-01 (actual); primary completion 2029-03-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Breathe Easier With Tadalafil Therapy for Dyspnea in COPD-PH
Acronym
BETTER COPD-PH
Condition
Chronic Obstructive Pulmonary Disease
Condition
Dyspnea
Intervention (Drug)
Tadalafil
Intervention (Drug)
Placebo
Lead sponsor
VA Office of Research and Development (class: US federal agency)
Collaborator
VA Boston Healthcare System (class: US federal agency)
Collaborator
Atlanta VA Medical Center (class: US federal agency)
Collaborator
VA Eastern Colorado Health Care System (class: US federal agency)
Collaborator
VA Nebraska Western Iowa Health Care System (class: US federal agency)

Record details

Record id
cardio:ct-nct05937854
Content hash
1da4d04c2863e0b90b1dd121804f70a5806844fb6b3cdf0624c17c1420240c34